Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 22, Kristen Kluska from Cantor Fitzgerald reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $105.00.

Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $166 million in total revenue for fiscal Q2 2025, with Crysvita revenue coming up to $120 million and Dojolvi revenue reaching $23 million.

The company reaffirmed its 2025 revenue guidance, with total revenue in the $640 million to $670 million range.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops, acquires, and commercializes novel products to treat genetic diseases. Its product portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza. In 2024, the company expanded its business through four products in five indications worldwide.

While we acknowledge the potential of RARE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RARE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.